From Casetext: Smarter Legal Research

Solomon Capital, LLC v. Lion Biotechnologies, Inc.

Supreme Court, Appellate Division, First Department, New York.
Apr 4, 2019
171 A.D.3d 467 (N.Y. App. Div. 2019)

Summary

finding that although terms like "massive investors" and "high-value investors" were "partially hyperbolic," they were nevertheless "concrete factual representations"

Summary of this case from Avalanche IP, LLC v. FAM, LLC

Opinion

8896 Index 651881/16

04-04-2019

SOLOMON CAPITAL, LLC, et al., Plaintiffs–Respondents, v. LION BIOTECHNOLOGIES, INC., Defendant–Appellant.

Troy Gould PC, Los Angeles, CA (Russell I. Glazer of the bar of the State of California, admitted pro hac vice, of counsel), for appellant. Proskauer Rose LLP, New York (Mark D. Harris of counsel), for respondents.


Troy Gould PC, Los Angeles, CA (Russell I. Glazer of the bar of the State of California, admitted pro hac vice, of counsel), for appellant.

Proskauer Rose LLP, New York (Mark D. Harris of counsel), for respondents.

Sweeny, J.P., Manzanet–Daniels, Kern, Oing, Singh, JJ.

Order, Supreme Court, New York County (O. Peter Sherwood, J.), entered August 15, 2018, which, to the extent appealed from as limited by the briefs, granted plaintiffs' motion to dismiss the eleventh affirmative defense and the first through fourth counterclaims as against plaintiffs Solomon Capital, LLC, Solomon Capital 401(k) Trust, and Solomon Sharbat, unanimously reversed, on the law, with costs, and the motion denied.

Accepting the allegations in the answer as true, and according defendant the benefit of every possible favorable inference, we find that the eleventh affirmative defense and first through fourth counterclaims are adequately pleaded. In support of the eleventh affirmative defense and first counterclaim alleging fraudulent inducement (see Eurycleia Partners, LP v. Seward & Kissel, LLP , 12 N.Y.3d 553, 559, 883 N.Y.S.2d 147, 910 N.E.2d 976 [2009] ), defendant alleges, as relevant herein, that, during a conference call with its CEO and CFO, plaintiff Solomon Sharbat, who was at the time a registered broker dealer with the Financial Industry Regulatory Authority (FINRA), represented, on behalf of himself and the other plaintiffs, that he had previously run a publicly traded U.S. company, that he had raised hundreds of millions of dollars for other biotech companies, that he had "massive investors" who were prepared to invest in defendant, and that these investments were "a done deal." Sharbat allegedly later asserted that he "had obtained high-value investors for [defendant] in Israel."

The statement that investments were "a done deal" is mere puffery; it has no fixed meaning (see Sidamonidze v. Kay , 304 A.D.2d 415, 757 N.Y.S.2d 560 [1st Dept. 2003] ).

However, Sharbat's statements that he had "massive investors" who were prepared to invest in defendant and that he "had obtained high-value investors for [defendant] in Israel," while partially hyperbolic, make concrete factual representations that go beyond mere puffery. Simply stated, Sharbat asserted that he had investors lined up and ready to go, when in fact he had none. Since plaintiffs were retained by defendant to bring investors in, these statements constitute misrepresentations of material facts for purposes of the fraudulent inducement counterclaim (see Sokolow, Dunaud, Mercadier & Carreras v. Lacher , 299 A.D.2d 64, 70, 747 N.Y.S.2d 441 [1st Dept. 2002] ). Finally, the statements that Sharbat had previously run a publicly traded U.S. company and that he had raised hundreds of millions of dollars for other biotech companies are concrete and measurable misrepresentations about Sharbat's experience (see White v. Davidson , 150 A.D.3d 610, 611, 55 N.Y.S.3d 223 [1st Dept. 2017] ).

It is undisputed that defendant adequately alleged scienter. In addition, it adequately alleged justifiable reliance (see Knight Sec. v. Fiduciary Trust Co. , 5 A.D.3d 172, 173, 774 N.Y.S.2d 488 [1st Dept. 2004] ). Thus, defendant adequately pleaded its affirmative defense of fraudulent inducement seeking rescission of the parties' agreement (see People v. Credit Suisse Sec. [USA] LLC , 31 N.Y.3d 622, 639, 82 N.Y.S.3d 295, 107 N.E.3d 515 [2018] [Paul G. Feinman, J., concurring]; Jack Kelly Partners LLC v. Zegelstein , 140 A.D.3d 79, 85, 33 N.Y.S.3d 7 [1st Dept. 2016], lv dismissed 28 N.Y.3d 1103, 45 N.Y.S.3d 364, 68 N.E.3d 92 [2016] ).

Defendant stated a counterclaim for fraudulent inducement by pleading the additional element of damages, in the form of expenses incurred, at Sharbat's insistence, in retaining nonparty investment bank New World Merchant Services LLC to prepare for a securities offering anticipated based on investment monies promised by plaintiffs. Defendant was not required to plead its damages with particularity; CPLR 3016(b) requires only that, for claims or defenses based on fraud, "the circumstances constituting the wrong shall be stated in detail [emphasis added]" (see A.S. Rampell, Inc. v. Hyster Co. , 3 N.Y.2d 369, 383, 165 N.Y.S.2d 475, 144 N.E.2d 371 [1957] ; Kensington Publ. Corp. v. Kable News Co. , 100 A.D.2d 802, 802, 474 N.Y.S.2d 524 [1st Dept. 1984] ).

The allegations that plaintiffs failed to disclose a FINRA investigation into Sharbat and the resulting FINRA complaint and eventual default judgment barring him from serving as a broker-dealer state a counterclaim for fraudulent concealment, under the special facts doctrine (see P.T. Bank Cent. Asia, N.Y. Branch v. ABN AMRO Bank N.V. , 301 A.D.2d 373, 376, 378, 754 N.Y.S.2d 245 [1st Dept. 2003] ). The initiation of the investigation was known to plaintiffs but was not a matter of public record and could not be discovered by defendant. Moreover, Sharbat was declining to cooperate with the investigation, with the predictable result that he ended up losing his broker-dealer license. Sharbat's being stripped of a financial license by a regulatory authority for impropriety could reasonably be expected to destroy defendant's confidence in him, whether or not the license was being used in their financial transaction.

In support of the counterclaim for breach of fiduciary duty, defendant alleges that plaintiffs were retained to "broker" investments for it by "represent[ing] it in its efforts to obtain investors both in the United States and abroad, in Israel," and that they advised defendant to retain New World "to provide investment banking services for an offering that would be funded from the investments [they] would broker." Defendant further alleges that plaintiffs billed it for more than $ 135,000 in expenses that they claimed they had incurred in their efforts to secure investors, and that, at plaintiffs' instance, defendant gave plaintiffs a promissory note in the amount of $ 135,000, plus 67,500 shares of stock, as well as a right to participate in the next round of financing "on the same terms offered to the investors that [plaintiffs] would bring to [defendant]." These allegations plead a broker-principal relationship sufficient to impose a fiduciary duty on plaintiffs vis-a-vis defendant (see EBC I, Inc. v. Goldman, Sachs & Co. , 5 N.Y.3d 11, 19–20, 799 N.Y.S.2d 170, 832 N.E.2d 26 [2005] ). Plaintiffs' fiduciary role carried with it a duty to disclose material facts, including developments and filings in the FINRA investigation (see Allen v. WestPoint–Pepperell, Inc. , 945 F.2d 40, 45 [2d Cir. 1991] ). Defendant alleges that plaintiffs negligently misrepresented that they were able to represent it in obtaining investors and facilitating the issuance of securities to raise capital for it, that they were skilled in obtaining financing from "high-value investors," that they "had qualified, high-value investors who were to invest in [defendant]," and that plaintiffs themselves were qualified to invest in defendant. Defendant further alleges that plaintiffs made these misrepresentations with the intent of inducing it to rely on them and that it relied on the misrepresentations to its detriment by, among other things, incurring fees and expenses in retaining New World and attempting to make a securities offering with New World. These allegations state a counterclaim for negligent misrepresentation (see Kimmell v. Schaefer , 89 N.Y.2d 257, 263–264, 652 N.Y.S.2d 715, 675 N.E.2d 450 [1996] ; Krog Corp. v. Vanner Group, Inc. , 158 A.D.3d 914, 918, 72 N.Y.S.3d 178 [3d Dept. 2018] ).


Summaries of

Solomon Capital, LLC v. Lion Biotechnologies, Inc.

Supreme Court, Appellate Division, First Department, New York.
Apr 4, 2019
171 A.D.3d 467 (N.Y. App. Div. 2019)

finding that although terms like "massive investors" and "high-value investors" were "partially hyperbolic," they were nevertheless "concrete factual representations"

Summary of this case from Avalanche IP, LLC v. FAM, LLC

noting that although one statement made during a conference call was "mere puffery," other statements were actionable

Summary of this case from Avalanche IP, LLC v. FAM, LLC
Case details for

Solomon Capital, LLC v. Lion Biotechnologies, Inc.

Case Details

Full title:Solomon Capital, LLC, et al., Plaintiffs-Respondents, v. Lion…

Court:Supreme Court, Appellate Division, First Department, New York.

Date published: Apr 4, 2019

Citations

171 A.D.3d 467 (N.Y. App. Div. 2019)
98 N.Y.S.3d 26
2019 N.Y. Slip Op. 2621

Citing Cases

PC Connection, Inc. v. Int'l Bus. Machs. Corp.

" Solomon Cap., LLC v. Lion Biotechnologies, Inc., 171 A.D.3d 467, 468 (2019); see also Doe v. Uber Techs.,…

One River Run Acquisition, LLC v. Milde

Had the parties contemplated the Individual Defendants playing such a prominent and necessary role, the…